Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1Phase 1 1

Status

Completed 2Active not recruiting 2Unknown 1Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Breast Neoplasms 2Vomiting 1Uterine Cervical Neoplasms 1Trigger Finger Disorder 1Sarcoma, Alveolar Soft Part 1Renal Insufficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Pain 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoplasm Metastasis 1Nausea 1Mucositis 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Mast-Cell 1Leukemia, Hairy Cell 1

Interventions

Dexamethasone 338Bortezomib 188Lenalidomide 186Cyclophosphamide 166Melphalan 124Calcium Dobesilate 108daratumumab 95fludarabine phosphate 69carfilzomib 69pomalidomide 68Peripheral Blood Stem Cell Transplantation 64Filgrastim 56Thalidomide 55Busulfan 53Mycophenolic Acid 52Tacrolimus 45Granulocyte Colony-Stimulating Factor 45ixazomib 43fludarabine 42Whole-Body Irradiation 40Cyclosporine 35Etoposide 33dexamethasone acetate 31Antilymphocyte Serum 31isatuximab 29dexamethasone 21-phosphate 26Prednisone 26elotuzumab 25Biopsy 25auricularum 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Multiple Myeloma × Acetaminophen × Clear all
NCT04268498 2026-03-24

ADVANCE

University of Miami

Phase 2 Active not recruiting
310 enrolled
Plasma cell

Multiple Myeloma

NCT05896228 2026-03-11

Iber-KDd

University of Miami

Phase 2 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT05704049 2025-12-29

IZALCO

Sanofi

Phase 2 Active not recruiting
118 enrolled
Plasma cell

Multiple Myeloma

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01985126 2018-06-25

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Janssen Research & Development, LLC

Phase 2 Completed
124 enrolled 18 charts
Plasma cell

Multiple Myeloma

NCT00899847 2017-10-20

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Stanford University

Phase 2 Completed
9 enrolled 15 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡